Artiva Biotherapeutics (NASDAQ:ARTV) Receives "Buy" Rating from Needham & Company LLC

Key Points

• Artiva Biotherapeutics has received a "Buy" rating from Needham & Company with a target price of $18.00, while maintaining a consensus rating of "Moderate Buy" with a price target of $17.00.
• The company's stock is currently trading around $2.77, showing a significant fluctuation with a twelve-month low of $1.47 and a high of $15.49.
• CEO Fred Aslan recently sold 25,500 shares at approximately $2.73 each, decreasing his position in the company by 6.19%.

Artiva Biotherapeutics (NASDAQ:ARTV - Get Free Report)'s stock had its "buy" rating reissued by Needham & Company LLC in a research note issued to investors on Friday,Benzinga reports. They currently have a $18.00 target price on the stock.

Separately, Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Artiva Biotherapeutics in a report on Wednesday, October 8th. Four research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $17.00.

Artiva Biotherapeutics Stock Performance

Shares of NASDAQ ARTV opened at $2.77 on Friday. Artiva Biotherapeutics has a twelve month low of $1.47 and a twelve month high of $15.49. The stock's 50 day moving average price is $2.85 and its 200-day moving average price is $2.42.

Artiva Biotherapeutics (NASDAQ:ARTV - Get Free Report) last posted its quarterly earnings results on Wednesday, August 6th. The company reported ($0.87) EPS for the quarter, missing analysts' consensus estimates of ($0.84) by ($0.03). As a group, research analysts anticipate that Artiva Biotherapeutics will post -4.95 EPS for the current fiscal year.

Insider Transactions at Artiva Biotherapeutics

In other Artiva Biotherapeutics news, CEO Fred Aslan sold 25,500 shares of the business's stock in a transaction on Friday, August 15th. The shares were sold at an average price of $2.73, for a total transaction of $69,615.00. Following the sale, the chief executive officer owned 386,693 shares of the company's stock, valued at $1,055,671.89. The trade was a 6.19% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. 21.40% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in ARTV. Ground Swell Capital LLC purchased a new position in shares of Artiva Biotherapeutics during the 2nd quarter valued at $38,000. Y Intercept Hong Kong Ltd purchased a new position in shares of Artiva Biotherapeutics during the 2nd quarter valued at $48,000. Bridgeway Capital Management LLC purchased a new position in shares of Artiva Biotherapeutics during the 2nd quarter valued at $53,000. Qube Research & Technologies Ltd purchased a new position in shares of Artiva Biotherapeutics during the 2nd quarter valued at $58,000. Finally, Jane Street Group LLC purchased a new position in shares of Artiva Biotherapeutics during the 2nd quarter valued at $67,000.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.